Research and development daily Johnson-Johnson Ibtini Unilitoxi monoantigen monotherapy CLL was approved in Europe

(2020.09.08 RESEARCHNEWS) Novart's high dose Enerzair Breezhaler significantly reduced the rate of moderate to severe asthma acute onset; We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
(click on the title, read the original article) Novartis high dose Enerzair Breezhaler significantly reduced the rate of moderate to severe asthma acute onset days ago, Novartis announced that in medium or large doses of long-acting beta-2 inhibitor agonists (LABA)/inhaled corticosteroids (ICS) In patients with uncontrollable asthma, a large daily dose of Enerzair Breezhaler combination (acetic aciddatero/Glon bromide/Mormisson, IND/GLY/MF) significantly reduces the acute onset rate of moderate or severe asthma compared to one medium dose per day.
the clinical success of phase IV in patients with PAH who were underreacted by PDE5i treatment, Bayer announced the positive results of phase IV study REPRACE at the 2020 European Respiratory Society (ERS) Virtual Annual Meeting.
In this study, moderate-risk pulmonary hypertension (PAH) adult patients who did not respond enough to receiving phosphate dylase-5 inhibitors (PDE5i) were transferred to Ademas (riociguat, Leosi) therapy, and the study reached the primary endpoint of compounding.
Zhengda Qing and another bio-similar drug to start Phase III clinical recently, Zheng Tianqing to start the Patoju single anti-injection (previously used name: TQB2440 injection) Phase III clinical evaluation TQB 2440 Injection/Padet Combined Quercetojudan anti-Gadositamine treatment of early or local late ER/PR-negative HER2-positive breast cancer patients in the effectiveness and safety of multi-center, randomized double-blind, parallel control phase III clinical studies.
(Drug Approval) Johnson and Johnson BTK inhibitor Ibtinie Unitoni monoantigen monotherapy CLL was approved in Europe recently, Johnson and Johnson Janssen announced that the European Commission has granted its Imbruvica (Ibtinib) Ibtinib first-line treatment of chronic lymphocytic leukemia (CLL) adult patients on the market approval.
Roche PD-L1 inhibitors in China were approved for non-small cell lung cancer and other 4 clinical approvals today, according to the CDE official website of the latest publicity, Roche PD-L1 inhibitor Tecentriq (atezolizumab, atili pearl monoanti) was approved again 4 clinical.
The proposed development of adaptive disorders is: atili pearl monoanti-anti-combination tiragolumab, for patients with stage III non-small cell lung cancer with no progression after platinum-containing programme chemotherapy; Treatment after arterial chemotherapy embolism (TACE); atilijutin monoantigen anti-combination low-dose radiotherapy, cisplatin/carptonin, etoposide, treatment of broad-stage small cell lung cancer; atili pearl monoantigen and beva bead mono-combination carbohydrate or cisplatin and etoposide for untreated patients with extensive stage small cell lung cancer.
6 new drugs approved clinically to develop treatment of vicid d'a, cancer, stroke medium CDE latest publicity, a number of new drugs to obtain clinical trials implied permission.
's TAK-994 tablets are intended to develop phobias for onset narnamosis; INcyte/Reding Pharmaceuticals' INCMGA00012 injections are intended to develop adhesives for non-surgical, local recurrence or metastatic tube squamous cell carcinoma that have not previously underwent systemic chemotherapy; and Lumosa Therapeutics/Shanghai Pharmaceutical's injection with LT3001 to develop adaptations for acute stroke stroke; and SK Life Science's Cenobamate tablets are intended to develop adaptations for partial seizures in adult patients; Jansen's JNJ-73763989 injections are intended to develop adaptations for chronic hepatitis B virus (HBV) infection and chronic HDV infection in hepatitis patients with HBV/HDV combined infections; and GST-HG121 for chronic hepatitis B (HBV) treatment in Guangshengtang Pharmaceuticals.
Hengrui Pharmaceutical apple acid famini capsule was approved to carry out clinical trials on the 8th, Hengrui Pharmaceuticals announced that the company and subsidiary Shanghai Hengrui Pharmaceutical Co., Ltd. apple acid famini capsules recently received the Approval Notice for Drug Clinical Trials approved by the State Drug Administration, and will soon start clinical trials.
antipsychotic drug "fluorosterol tablets" the first through the consistency evaluation 7, the State Drug Administration website shows that Ningbo Dahong eagle pharmaceutical company's fluorosterol tablet supplement application was approved, for the first variety through the consistent evaluation.